TOPCAT: Aldo-Antagonist Falls Short but Impresses in HFPEFTOPCAT: Aldo-Antagonist Falls Short but Impresses in HFPEF
Spironolactone failed on the trial's primary end point, but its effect on HF hospitalizations has convinced some experts it's worth using in a disorder without other good drug options. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 19, 2013 Category: Cardiology Tags: Cardiology News Source Type: news
AHA: Decision on Spironolactone in HF a Toss-Up? (CME/CE)
DALLAS (MedPage Today) -- The TOPCAT trial evaluating spironolactone in patients with heart failure and preserved ejection fraction did not meet its primary endpoint, but there was some evidence of benefit, a researcher reported here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 19, 2013 Category: Cardiology Source Type: news
New Study Shows Spironolactone Reduces Heart Failure Hospitalizations, But Not Mortality
Spironolactone reduces the risk of repeated hospitalizations for heart failure. (Source: BWH News)
Source: BWH News - November 18, 2013 Category: Hospital Management Source Type: news
New Study Shows Spironolactone Reduces Heart Failure Hospitalizations, But Not Mortality
Spironolactone reduces the risk of repeated hospitalizations for heart failure. (Source: BWH for Journalists)
Source: BWH for Journalists - November 18, 2013 Category: Research Source Type: news
New Study Shows Spironolactone Reduces Heart Failure Hospitalizations, But Not Mortality
Spironolactone reduces the risk of repeated hospitalizations for heart failure. (Source: BWH News)
Source: BWH News - November 18, 2013 Category: Hospital Management Source Type: news
Featured in NEJM Journal Watch: Spironolactone Mitigates Rosacea Risk (FREE)
By the NEJM Journal Watch Editors
In a large population-based analysis, spironolactone users … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 5, 2013 Category: Primary Care Source Type: news
Race Tied to Outcomes with HF Drug (CME/CE)
(MedPage Today) -- African Americans with heart failure and reduced left ventricular output may not derive the same benefit from spironolactone as other ethnic groups, a post-hoc analysis of the randomized RALES trial found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 16, 2013 Category: Cardiology Source Type: news
Spironolactone Improves Arrhythmogenic Substrate in HFSpironolactone Improves Arrhythmogenic Substrate in HF
Find out how this mineralocorticoid receptor antagonist reduces sudden cardiac death in patients with heart failure. Journal of Cardiovascular Electrophysiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 31, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Spironolactone of Benefit in Resistant HypertensionSpironolactone of Benefit in Resistant Hypertension
Daytime blood pressure measured by 24-hour ambulatory blood-pressure monitoring was reduced by 8.9/3.7 mm Hg, report investigators. The data suggest that the addition of spironolactone might be beneficial in this hard-to-treat patient population already receiving multiple antihypertensive medications, they add. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 17, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
Spironolactone provides benefit in resistant hypertension, small study shows
Daytime blood pressure measured by 24-hour ambulatory blood-pressure monitoring was reduced by 8.9/3.7 mm Hg, report investigators. The data suggest that the addition of spironolactone might be beneficial in this hard-to-treat patient population already receiving multiple antihypertensive medications, they add. (Source: theHeart.org)
Source: theHeart.org - June 17, 2013 Category: Cardiology Source Type: news
Bayer's New MRA Passes First TestBayer's New MRA Passes First Test
Patients treated with the drug, known only as BAY94-8862 at the moment, had a significantly lower risk of hyperkalemia than patients treated with spironolactone, as well as a lower risk of worsening renal failure. The drug also reduced BNP levels as much as spironolactone. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 31, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
New mineralocorticoid-receptor antagonist passes in phase 2 study
Patients treated with the drug, known only as BAY94-8862 at the moment, had a significantly lower risk of hyperkalemia than patients treated with spironolactone, as well as a lower risk of worsening renal failure. The drug also reduced BNP levels as much as spironolactone. (Source: theHeart.org)
Source: theHeart.org - May 30, 2013 Category: Cardiology Source Type: news
BAY 94-8662 shows promise in HF patients with reduced renal function.
BAY 94-8662 - a next generation mineralocorticoid receptor antagonist (MRA) - is at least as effective as spironolactone in reducing biomarkers of hemodynamic stress, and associated with a lower incidence of hyperkalaemia and worsening renal function (WRF), reported the phase II ARTs study.
Read more
Topics:
Heart Failure (HF) (Source: ESC News and Press)
Source: ESC News and Press - May 26, 2013 Category: Cardiology Source Type: news
Digoxin toxicity: check the magnesium level!
3 out of 5 stars
Digoxin Toxicity with Normal Digoxin and Serum Potassium Levels: Beware of Magnesium, the Hidden Malefactor. Rao MPR et al. J Emerg Med 2013 May 16 [Epub ahead of print]
Abstract
This case report from Oman describes at 66-year-old woman (inexplicably described as “elderly”) who presented to hospital with one day of nausea, vomiting, abdominal distress, and palpitations. Her medications included furosemide, spironolactone, digoxin, carvedilol, lisinopril, metformin, and calcium. Initial EKGs showed evidence of junctional tachycardia and digoxin effect.
The treating physicians initially consider...
Source: The Poison Review - May 23, 2013 Category: Toxicology Authors: Leon Tags: Medical digitalis digoxin toxicity hypomagnesemia magnesium potassium Source Type: news
Benefits of diastolic function improvement in heart failure questioned
The importance of left ventricular diastolic function improvement in patients with heart failure with preserved ejection fraction has been questioned, after researchers found that treatment with spironolactone resulted in some functional improvements but failed to impact on patients’ exercise capacity. (Source: MedWire News - Cardiology)
Source: MedWire News - Cardiology - March 4, 2013 Category: Cardiology Source Type: news
